Suppr超能文献

新型苯硝唑制剂的研发:恰加斯病寄生虫血症降低方面的物理化学特性及体内评价

Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease.

作者信息

Palmeiro-Roldán Ricardo, Fonseca-Berzal Cristina, Gómez-Barrio Alicia, Arán Vicente J, Escario José A, Torrado-Durán Susana, Torrado-Santiago Santiago

机构信息

Department of Pharmaceutical Technology, Faculty of Pharmacy, Complutense University, Plaza Ramón y Cajal s/n, Madrid 28040, Spain.

CEI Campus Moncloa, UCM-UPM & CSIC, Madrid, Spain; Department of Parasitology, Faculty of Pharmacy, Complutense University, Plaza Ramón y Cajal s/n, Madrid 28040, Spain.

出版信息

Int J Pharm. 2014 Sep 10;472(1-2):110-7. doi: 10.1016/j.ijpharm.2014.06.015. Epub 2014 Jun 10.

Abstract

This work aims to develop novel benznidazole (BZN) solid dispersions (SD) to improve its solubility and bioavailability properties. Low-substituted hydroxypropylcellulose (L-HPC) and sodium deoxycholate (NaDC) were evaluated as carriers. BZN solid dispersions containing different ratios of carrier were prepared by a freeze-drying process and characterized by SEM, powder X-ray diffraction (XRD), differential scanning calorimetry (DSC) and dissolution studies. The reduced BNZ crystallinity in the new formulations was confirmed by XRD, and supported by DSC. BNZ:L-HPC solid dispersion at a 1:3 ratio (w/w) (SD-1:3 L-HPC) improved the BNZ dissolution rate (85% at 5 min) in comparison with BNZ raw material (23% at 5 min). However, NaDC formulations showed a prolonged release (24% at 30 min for SD-1:3 NaDC), due to the formation of a sustained release matrix in acidic medium. In vivo studies performed in a murine model of Chagas disease showed that the formulation achieving the highest parasitemia suppression at a low dose of 25mg/kg/day after five days of treatment was SD-1:3 L-HPC (60% of parasitemia suppression versus 33% of suppression exerted by BNZ), suggesting that BNZ:L-HPC systems enhance the bioavailability of the drug.

摘要

本研究旨在开发新型苯硝唑(BZN)固体分散体(SD),以改善其溶解度和生物利用度。评估了低取代羟丙基纤维素(L-HPC)和脱氧胆酸钠(NaDC)作为载体。通过冷冻干燥法制备了含有不同载体比例的BZN固体分散体,并通过扫描电子显微镜(SEM)、粉末X射线衍射(XRD)、差示扫描量热法(DSC)和溶出度研究对其进行了表征。XRD证实了新制剂中BNZ结晶度的降低,并得到了DSC的支持。与BZN原料药(5分钟时为23%)相比,1:3比例(w/w)的BNZ:L-HPC固体分散体(SD-1:3 L-HPC)提高了BNZ的溶出速率(5分钟时为85%)。然而,由于在酸性介质中形成了缓释基质,NaDC制剂显示出缓释效果(SD-1:3 NaDC在30分钟时为24%)。在恰加斯病小鼠模型中进行的体内研究表明,在25mg/kg/天的低剂量治疗5天后,实现最高寄生虫血症抑制率的制剂是SD-1:3 L-HPC(寄生虫血症抑制率为60%,而BZN为33%),这表明BNZ:L-HPC体系提高了药物的生物利用度。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验